PortfoliosLab logo
Jasper Therapeutics Inc (JSPRW)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

IPO Date

Jan 10, 2020

Highlights

EPS (TTM)

-$3.84

Total Revenue (TTM)

$1.17M

Gross Profit (TTM)

$288.00K

EBITDA (TTM)

-$10.97M

Year Range

$0.06 - $0.25

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Jasper Therapeutics Inc

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period

Jasper Therapeutics Inc (JSPRW) returned -51.19% year-to-date (YTD) and -48.75% over the past 12 months.


JSPRW

YTD

-51.19%

1M

15.17%

6M

-48.75%

1Y

-48.75%

3Y*

-17.11%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

0.51%

1M

6.15%

6M

-2.00%

1Y

12.92%

3Y*

12.68%

5Y*

14.19%

10Y*

10.85%

*Annualized

Monthly Returns

The table below presents the monthly returns of JSPRW, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-15.48%-18.48%-1.17%-37.76%15.17%-51.19%
202425.00%122.10%-18.05%-21.15%35.89%2.56%8.75%-0.28%-7.79%-0.10%0.00%5.11%162.50%
2023383.33%6.83%29.12%-15.05%-17.72%0.29%-28.67%-39.40%-17.49%120.00%-27.82%0.76%166.67%
2022-51.36%-60.49%-7.93%-0.04%-30.77%-49.44%-16.48%44.74%-45.45%-16.67%10.00%-45.45%-97.96%
2021-2.63%-12.16%-6.92%21.49%-3.29%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of JSPRW is 36, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of JSPRW is 3636
Overall Rank
The Sharpe Ratio Rank of JSPRW is 2727
Sharpe Ratio Rank
The Sortino Ratio Rank of JSPRW is 6363
Sortino Ratio Rank
The Omega Ratio Rank of JSPRW is 6767
Omega Ratio Rank
The Calmar Ratio Rank of JSPRW is 2020
Calmar Ratio Rank
The Martin Ratio Rank of JSPRW is 55
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Jasper Therapeutics Inc (JSPRW) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Jasper Therapeutics Inc Sharpe ratios as of May 30, 2025 (values are recalculated daily):

  • 1-Year: -0.39
  • All Time: -0.18

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Jasper Therapeutics Inc compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


Jasper Therapeutics Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Jasper Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Jasper Therapeutics Inc was 98.93%, occurring on Dec 28, 2022. The portfolio has not yet recovered.

The current Jasper Therapeutics Inc drawdown is 94.61%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.93%Oct 14, 2021243Dec 28, 2022
-25.45%Oct 5, 20216Oct 12, 20211Oct 13, 20217
-12.5%Sep 28, 20212Sep 29, 20213Oct 4, 20215
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Jasper Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Jasper Therapeutics Inc, comparing actual results with analytics estimates.


-6.00-5.00-4.00-3.00-2.00-1.000.00AprilMayJuneJulyAugustSeptemberOctoberNovemberDecember2021FebruaryMarchAprilMayJune
-0.69
0
Actual
Estimate

Valuation

The Valuation section provides an overview of how Jasper Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for JSPRW relative to other companies in the Biotechnology industry. Currently, JSPRW has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for JSPRW in comparison with other companies in the Biotechnology industry. Currently, JSPRW has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items